Aslan, which develops treatments for tumours prevalent in Asian patients, has secured funding from investors including Accuron and Tianda.

Cambridge University's research tools reaches a global audience as Cambridge Enterprise partners Ximbio.

Cytos Biotechnology and spinout Kuros Biosurgery come together to create Kuros Biosciences through a mutual exchange of shares to lead the way in tissue repair and regeneration.

Welltok was one of two patient management platforms to raise more than $40m last week, showing the ongoing expansion of the sector.

Takeda Pharmaceuticals has backed a round that will help Prosetta continue research and development into treatments for a range of central nervous system disorders.

NxThera, also backed by Mitsui and American Medical Systems, aims to use water vapour-based treatments to fight prostate and kidney cancer.

Corporate-backed Welltok has boosted its total funding to approximately $128m, also acquiring marketing platform Silverlink Communications.